Chargement en cours...
Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy
BACKGROUND: We previously reported changes of body composition determined by dual-energy X-ray absorptiometry after treatment with ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. In that study, mean body weight was decreased by 3.5 kg (4.3% of the baseline value) after ipraglifloz...
Enregistré dans:
| Publié dans: | J Clin Med Res |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elmer Press
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6436566/ https://ncbi.nlm.nih.gov/pubmed/30937121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr3785 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|